ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

ImageneBio IncNASDAQ: IMA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) declines year over year

Q1 FY2026 weighted avg shares (diluted) of 11.21M shares fell 76.8% year over year, behind the -59.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at -48.8% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -76.8% toward the trailing-twelve-month pace of -59.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
11.21M+0.3% QoQ
Last fiscal yearDec 2025
4.87M-89.9% YoY
LTMMar 2026
19.79M-59.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.8%——
1 year-89.9%——
3-year CAGR-48.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
4.87M USD
Year-over-year change
-89.9%
4-year CAGR
-39.3%

Weighted Avg Shares (Diluted) vs competitors

How IMA compares with its peers on the latest reported figures

  • IMA's LTM Mar 2026 weighted avg shares (diluted) of 19.79M shares is the 8th highest of the 9 companies compared; the peer median is 62.26M shares.
  • Its year-over-year change of -59.0% is the lowest of 9, against a peer median of +9.7%.
  • Over three fiscal years its annual growth of -48.8% compares with a peer median of +16.5%.
IMA Competitors Peer median
Weighted Avg Shares (Diluted) for IMA and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding IMA) 62.26M+9.7%+16.5%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.